Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient

Ann Oncol. 2011 Apr;22(4):991-993. doi: 10.1093/annonc/mdr028. Epub 2011 Feb 28.

Authors

S Wilgenhof¹, B Neyns²

Affiliations

¹ Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
² Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium. Electronic address: Bart.Neyns@uzbrussel.be.

PMID: 21357649
DOI: 10.1093/annonc/mdr028

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antigens, CD / immunology*
CTLA-4 Antigen
Female
Guillain-Barre Syndrome / chemically induced*
Guillain-Barre Syndrome / immunology
Humans
Ipilimumab
Melanoma / complications
Melanoma / drug therapy*
Middle Aged

Substances

Antibodies, Monoclonal
Antigens, CD
CTLA-4 Antigen
CTLA4 protein, human
Ipilimumab